These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11056593)

  • 1. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.
    Apfel SC; Schwartz S; Adornato BT; Freeman R; Biton V; Rendell M; Vinik A; Giuliani M; Stevens JC; Barbano R; Dyck PJ
    JAMA; 2000 Nov; 284(17):2215-21. PubMed ID: 11056593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nerve growth factor (NGF) in treatment of diabetic polyneuropathy. One hope less?].
    Quasthoff S; Hartung HP
    Nervenarzt; 2001 Jun; 72(6):456-9. PubMed ID: 11433707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291.
    McArthur JC; Yiannoutsos C; Simpson DM; Adornato BT; Singer EJ; Hollander H; Marra C; Rubin M; Cohen BA; Tucker T; Navia BA; Schifitto G; Katzenstein D; Rask C; Zaborski L; Smith ME; Shriver S; Millar L; Clifford DB; Karalnik IJ
    Neurology; 2000 Mar; 54(5):1080-8. PubMed ID: 10720278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
    Bonini S; Lambiase A; Rama P; Sinigaglia F; Allegretti M; Chao W; Mantelli F;
    Ophthalmology; 2018 Sep; 125(9):1332-1343. PubMed ID: 29653858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
    Ametov AS; Barinov A; Dyck PJ; Hermann R; Kozlova N; Litchy WJ; Low PA; Nehrdich D; Novosadova M; O'Brien PC; Reljanovic M; Samigullin R; Schuette K; Strokov I; Tritschler HJ; Wessel K; Yakhno N; Ziegler D;
    Diabetes Care; 2003 Mar; 26(3):770-6. PubMed ID: 12610036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
    Ziegler D; Hanefeld M; Ruhnau KJ; Hasche H; Lobisch M; Schütte K; Kerum G; Malessa R
    Diabetes Care; 1999 Aug; 22(8):1296-301. PubMed ID: 10480774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy.
    Wellmer A; Misra VP; Sharief MK; Kopelman PG; Anand P
    J Peripher Nerv Syst; 2001 Dec; 6(4):204-10. PubMed ID: 11800042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study.
    Hernández-Ojeda J; Cardona-Muñoz EG; Román-Pintos LM; Troyo-Sanromán R; Ortiz-Lazareno PC; Cárdenas-Meza MA; Pascoe-González S; Miranda-Díaz AG
    J Diabetes Complications; 2012; 26(4):352-8. PubMed ID: 22595020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.
    Beykin G; Stell L; Halim MS; Nuñez M; Popova L; Nguyen BT; Groth SL; Dennis A; Li Z; Atkins M; Khavari T; Wang SY; Chang R; Fisher AC; Sepah YJ; Goldberg JL
    Am J Ophthalmol; 2022 Feb; 234():223-234. PubMed ID: 34780798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human studies of recombinant human nerve growth factor and diabetic peripheral neuropathy.
    Freeman R
    Eur Neurol; 1999; 41 Suppl 1():20-6. PubMed ID: 10023125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
    Backonja M; Beydoun A; Edwards KR; Schwartz SL; Fonseca V; Hes M; LaMoreaux L; Garofalo E
    JAMA; 1998 Dec; 280(21):1831-6. PubMed ID: 9846777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.
    Apfel SC; Kessler JA; Adornato BT; Litchy WJ; Sanders C; Rask CA
    Neurology; 1998 Sep; 51(3):695-702. PubMed ID: 9748012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
    Polydefkis M; Arezzo J; Nash M; Bril V; Shaibani A; Gordon RJ; Bradshaw KL; Junor RW;
    J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
    Adams D; Suhr OB; Dyck PJ; Litchy WJ; Leahy RG; Chen J; Gollob J; Coelho T
    BMC Neurol; 2017 Sep; 17(1):181. PubMed ID: 28893208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy.
    Soin A; Bock G; Giordano A; Patel C; Drachman D
    Pain Physician; 2018 Mar; 21(2):179-190. PubMed ID: 29565948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The medial plantar and medial peroneal cutaneous nerve conduction studies for diabetic polyneuropathy.
    Altun Y; Demirkol A; Tumay Y; Ekmekci K; Unsal I; Koyluoglu AC; Ozkul Y
    Neurol Sci; 2011 Oct; 32(5):849-54. PubMed ID: 21720897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?
    Apfel SC
    Int Rev Neurobiol; 2002; 50():393-413. PubMed ID: 12198818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.
    Brock C; Hansen CS; Karmisholt J; Møller HJ; Juhl A; Farmer AD; Drewes AM; Riahi S; Lervang HH; Jakobsen PE; Brock B
    Br J Clin Pharmacol; 2019 Nov; 85(11):2512-2523. PubMed ID: 31338868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Oral Mixed Tocotrienols in Diabetic Peripheral Neuropathy: A Randomized Clinical Trial.
    ; Hor CP; Fung WY; Ang HA; Lim SC; Kam LY; Sim SW; Lim LH; Choon WY; Wong JW; Ch'ng ASH; Beh KKM; Wee HC; Ong LM; Khan NAK; Sulaiman SAS; Shuaib IL; Bakar A; Yusof Y; Yusof YM; Abu Bakar F; Tang WS; Teh HL; Wahid NA; Saaidin S; Idris N; Yoon CK; Ong HN; Ganapathy JT; Loo CE; Samy MM; Zainal H; Dharan SCS; Ooi BY; Teoh PY; Tye YL; Yeoh CA; Low DW; Looi I; Yuen KH
    JAMA Neurol; 2018 Apr; 75(4):444-452. PubMed ID: 29379943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.